CinCor is a clinical-stage biopharmaceutical company focused on developing our lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CIN-107 is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland. CIN-107 has been designed to use a differentiated mechanism of action, direct inhibition of aldosterone synthase production, with the goal of providing an improved treatment for patients suffering from hypertension, or high blood pressure.
We are evaluating the efficacy and safety profile of CIN-107 as a potential treatment for the broader hypertensive population, including different subpopulations of hypertensive patients who have not achieved blood pressure control despite treatment. We are conducting a Phase 2 clinical trial, which we refer to as our BrigHtn trial, of CIN-107 in patients whose blood pressure is not controlled despite treatment with three antihypertensive agents, including a diuretic, which is referred to as treatment resistant hypertension, or rHTN. We have recently initiated a separate Phase 2 clinical trial, which we refer to as our HALO trial, in patients with elevated aldosterone levels whose blood pressure is not controlled despite treatment with one antihypertensive agent, which is referred to as uncontrolled hypertension, or uHTN.
In addition to hypertension, we are developing CIN-107 for the treatment of primary aldosteronism, or PA, and we are exploring its utility in ameliorating complications of chronic kidney disease, or CKD. Earlier this year, we initiated a Phase 2 clinical trial of CIN-107 in patients with confirmed PA, which we refer to as our spark-PA trial, and plan to initiate a Phase 2 clinical trial in patients with CKD who have uncontrolled blood pressure in the first half of 2022.
The people behind CinCor Pharma are not only experienced, they’re phenomenal.
Marc de Garidel
Marc de Garidel has served as our Chief Executive Officer and a member of our board of directors since July 2021. Mr. de Garidel serves on the board of directors of Claris Biotherapeutics, Inc. Prior to September 2020, Mr. de Garidel served as the Chief Executive Officer of Corvidia Therapeutics, Inc. from January 2018 until their acquisition by Novo Nordisk A/S in August 2020. Mr. de Garidel also served as the Chief Executive Officer of Ipsen SA from November 2010 to July 2016, and has served as the chairman of Ipsen’s board of directors since November 2010. Mr. de Garidel started his career at Eli Lilly & Co and then served 15 years in multiple growing responsibility roles at Amgen in the US and Europe.
EVP, CFO and CBDO
Terry Coelho has served as our Executive Vice President, Chief Financial Officer and Chief Business Development Officer since November 2021. Previously, Ms. Coelho served as the Executive Vice President, Chief Financial Officer and Treasurer of BioDelivery Sciences International, Inc. from January 2019 to October 2021 and as Chief Financial Officer and Treasurer at Balchem Corporation from October 2017 to October 2018. She also held Chief Financial Officer and Chief Operating Officer roles for Diversey, Inc., and for Diversey Care, a division of Sealed Air Corporation, from October 2014 through September 2017. Previously, Ms. Coelho held senior finance leadership roles with Novartis Pharmaceuticals from 2007 through 2014, as well as roles of increasing responsiblilty in both finance and general management throughout her twenty year career with Mars, Incorporated. Terry has served on the board of directors for First Wave BioPharma since August 2021.
Catherine Pearce, DHSc
COO & co-founder
Catherine Pearce, M.B.A., D.HSc., co-founded our company in 2018 and has served as our Chief Operating Officer since May 2019. Previously, Ms. Pearce served as both the Chief Operating Officer of CinRx and the vice president, strategic alliances at Medpace from September 2015 until August 2021. Ms. Pearce also served as the Vice President, Research and Development at Teva Pharmaceutical Industries Ltd. from April 2013 until September 2015.
Mason W. Freeman, MD
EVP, Clinical Development
Mason Freeman, M.D., has served as our Executive Vice President, Clinical Development since August 2021, and as a member of our scientific advisory board since June 2019. Dr. Freeman also serves as a Venture Partner at 5AM Venture Management, LLC, a position he has held since May 2008. In addition, Dr. Freeman serves as the Director of the Massachusetts General Hospital’s Translational Research Center. Previously, Dr. Freeman served as a member of the board of directors of scPharmaceuticals Inc. from July 2018 to December 2020 and Crinetics Pharmaceuticals, Inc. from November 2015 to July 2019.
Senior Management Team
Yuan-Di Halvorsen, PhD
VP, Clinical Operations
Nadege Briancon-Eris, PhD
Senior Director, Program Management
VP, CMC and Quality Control
Justin Thompson, MS
VP, Business Development
James Healy, MD, PhD
David Allison, PhD
Maina Bhaman, MBA
Marc de Garidel
Chief Executive Officer
Jason Pitts, PhD
John F. Thero
June Lee, MD
Scientific Advisory Board
Morris Brown, MD
Professor of Endocrine Hypertension, Queen Mary, UK
Ulrich Granzer, PhD
Granzer Regulatory and Consulting Services
John Kastelein, MD
Emeritus Professor of Medicine at the Academic Medical Center (AMC) of the University of Amsterdam
Suzanne Oparil, MD
Professor of Medicine / Hypertension Program at University of Alabama
Patrick Rossignol, MD
Professor of Therapeutics, Nephrologist and Vascular Medicine Specialist, Université de Lorraine (France)
Philip T. Sager, MD
Former Chair - FDA Cardiovascular and Renal Advisory Committee
Bryan Williams, MD
Chair of Medicine at UCL, National Institute for Health Research Senior Investigator Emeritus (UK)